Tags

Type your tag names separated by a space and hit enter

Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19.
J Clin Microbiol. 2020 Jul 23; 58(8)JC

Authors+Show Affiliations

Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA ddr26@case.edu. Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

Pub Type(s)

Comparative Study
Evaluation Study
Letter

Language

eng

PubMed ID

32303564

Citation

Rhoads, Daniel D., et al. "Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 From Nasopharyngeal and Nasal Swabs From Individuals Diagnosed With COVID-19." Journal of Clinical Microbiology, vol. 58, no. 8, 2020.
Rhoads DD, Cherian SS, Roman K, et al. Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19. J Clin Microbiol. 2020;58(8).
Rhoads, D. D., Cherian, S. S., Roman, K., Stempak, L. M., Schmotzer, C. L., & Sadri, N. (2020). Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19. Journal of Clinical Microbiology, 58(8). https://doi.org/10.1128/JCM.00760-20
Rhoads DD, et al. Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 From Nasopharyngeal and Nasal Swabs From Individuals Diagnosed With COVID-19. J Clin Microbiol. 2020 Jul 23;58(8) PubMed PMID: 32303564.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19. AU - Rhoads,Daniel D, AU - Cherian,Sree S, AU - Roman,Katharine, AU - Stempak,Lisa M, AU - Schmotzer,Christine L, AU - Sadri,Navid, Y1 - 2020/07/23/ PY - 2020/4/19/pubmed PY - 2020/8/6/medline PY - 2020/4/19/entrez KW - COVID-19 KW - SARS-CoV-2 KW - coronavirus KW - emergency use authorization KW - in vitro diagnostic KW - nucleic acid amplification KW - virology JF - Journal of clinical microbiology JO - J Clin Microbiol VL - 58 IS - 8 SN - 1098-660X UR - https://www.unboundmedicine.com/medline/citation/32303564/Comparison_of_Abbott_ID_Now_DiaSorin_Simplexa_and_CDC_FDA_Emergency_Use_Authorization_Methods_for_the_Detection_of_SARS_CoV_2_from_Nasopharyngeal_and_Nasal_Swabs_from_Individuals_Diagnosed_with_COVID_19_ L2 - http://jcm.asm.org/lookup/pmidlookup?view=long&pmid=32303564 DB - PRIME DP - Unbound Medicine ER -